×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: A Phase III, Randomized, Double-Blind, Placebo-Controlled, M
clinical
1,957 words
KG: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial ... (NCT05021536)
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
Contents
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial ... (NCT05021536)
Knowledge Graph
Related Hypotheses (13)
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.38
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Stress Granule Phase Separation Modulators
Score: 0.49
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Astrocyte-Mediated Neuronal Epigenetic Rescue
Score: 0.48
Biorhythmic Interference via Controlled Sleep Oscillations
Score: 0.41
Show 8 more
Related Analyses (5)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Related Experiments (2)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
See Also (15)
Section 253: Advanced Optogenetics and Chemogenetics fo
therapeutic · Pages share 4 hypotheses
Section 253: Advanced Optogenetics and Chemogenetics fo
therapeutic · Pages share 4 hypotheses
Section 204: Advanced Proteostasis and Protein Quality
therapeutic · Pages share 4 hypotheses
Section 201: Advanced Mitochondrial Biogenesis and PGC-
therapeutic · Pages share 4 hypotheses
Section 194: Advanced Mitochondrial Dynamics and Biogen
therapeutic · Pages share 4 hypotheses
Mitochondrial Replacement Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Mitochondrial Biogenesis Inducers in Neurodegeneration
therapeutic · Pages share 4 hypotheses
Neurodegeneration
disease · Pages share 4 hypotheses
A 6-month & 18-month Prospective, Randomized, Placebo-c
clinical · Pages share 4 hypotheses
A Phase 2 Double-Blind, Randomized, Placebo-Controlled
clinical · Pages share 4 hypotheses
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 4 hypotheses
A Phase 2b, Multicenter, Randomized, Double-Blind, Plac
clinical · Pages share 4 hypotheses
A Multicenter, Phase III, Randomized, Double Blind, Pla
clinical · Pages share 4 hypotheses
A Phase IIB, Randomized, Double-Blind, Placebo-Controll
clinical · Pages share 4 hypotheses
Optogenetically-Modified Neurons in Neurodegeneration R
cell · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (1 edges)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial ... (NCT05021536)
references
HDAC